Lupin is currently trading at Rs. 585.65, up by 0.30 points or 0.05% from its previous closing of Rs. 585.35 on the BSE.
The scrip opened at Rs. 588.10 and has touched a high and low of Rs. 589.70 and Rs. 583.45 respectively. So far 11,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 631.90 and a 52 week low of Rs. 412.15. The current market cap of the company is Rs. 26,195.00 crore.
The promoters holding in the company stood at 46.85% while Institutions and Non-Institutions held 43.40% and 9.75% respectively.
Pharma major, Lupin’s subsidiary - Lupin Pharmaceuticals Inc (collectively Lupin) has received final approval for its Levonorgestrel and Ethinyl Estradiol tablets USP, 0.1 mg / 0.02 mg from the United States Food and Drugs Administration (USFDA) to market a generic version of Watson Laboratories, Inc.’s Lutera 28 tablets. As per IMS MAT Sept 2012 sales, Lutera tablets had annual US sales of approximately $103.6 million.
Lupin’s Levonorgestrel and Ethinyl Estradiol tablets are a combined oral contraceptive indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Lupin will be marketing its generic product shortly.
Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: